Molecular profiling for personalized cancer care
- PMID: 22678423
- PMCID: PMC3484311
- DOI: 10.1007/s10585-012-9483-3
Molecular profiling for personalized cancer care
Abstract
The pace of genomic discoveries in the field of cancer is revolutionizing our understanding of the biological dynamics of cancerous growth and, at the same time, fueling research for newer and smarter cancer therapies to reverse the effects of these alterations. These dynamics are driving a tremendous paradigm shift in cancer diagnostics, drug development and clinical trial design with the hope of eliminating the current structure and approach of cancer care, to one which is driven by the underlying biology of the tumor and, thus highly personalized. Much of this paradigm shift has been fueled by the current availability of novel technologies, platforms and bioinformatic tools. Today, therapies are being rationally designed to target the precise genetic alterations with better clinical outcomes with reduced morbidity. Therefore, molecular profiling of tumors to identify the multiplicity of alterations in a tumor is an essential and necessary companion for targeted therapies.
Similar articles
-
Molecular tests and target therapies in oncology: recommendations from the Italian workshop.Future Oncol. 2021 Sep;17(26):3529-3539. doi: 10.2217/fon-2021-0286. Epub 2021 Jul 13. Future Oncol. 2021. PMID: 34254524
-
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.Pac Symp Biocomput. 2015:56-67. Pac Symp Biocomput. 2015. PMID: 25592568
-
Personalized oncology: recent advances and future challenges.Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Metabolism. 2013. PMID: 22999010 Review.
-
Personalized cancer genomics: the road map to clinical implementation.Clin Chem. 2012 Apr;58(4):661-3. doi: 10.1373/clinchem.2011.181073. Epub 2012 Feb 9. Clin Chem. 2012. PMID: 22322979 No abstract available.
-
Targeted therapy in cancer.Cancer Chemother Pharmacol. 2015 Dec;76(6):1113-32. doi: 10.1007/s00280-015-2861-1. Epub 2015 Sep 21. Cancer Chemother Pharmacol. 2015. PMID: 26391154 Free PMC article. Review.
Cited by
-
SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care.J Am Med Inform Assoc. 2016 Jul;23(4):701-10. doi: 10.1093/jamia/ocw015. Epub 2016 Mar 27. J Am Med Inform Assoc. 2016. PMID: 27018265 Free PMC article.
-
Adenocarcinoma involving the urinary bladder.BMJ Case Rep. 2023 Jul 18;16(7):e252747. doi: 10.1136/bcr-2022-252747. BMJ Case Rep. 2023. PMID: 37463778 Free PMC article.
-
Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.Autops Case Rep. 2018 Nov 30;8(4):e2018049. doi: 10.4322/acr.2018.049. eCollection 2018 Oct-Dec. Autops Case Rep. 2018. PMID: 30775324 Free PMC article.
-
Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study.J Natl Compr Canc Netw. 2014 Jun;12(6):847-52. doi: 10.6004/jnccn.2014.0079. J Natl Compr Canc Netw. 2014. PMID: 24925195 Free PMC article.
-
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Cell Cycle. 2013 Apr 15;12(8):1166-79. doi: 10.4161/cc.24479. Epub 2013 Apr 2. Cell Cycle. 2013. PMID: 23549172 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources